News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|December 13, 2024

PTSD in Society

Author(s)Arash Javanbakht, MD, Matthew Robinson, PhD, Tory Woodard, NP

Key Takeaways

A panelist discusses how posttraumatic stress disorder (PTSD) permeates modern society at multiple levels, from individuals coping with personal trauma to collective trauma responses that shape community behaviors and social structures.

Episodes in this series

4 experts are featured in this series.

EP. 1 PTSD in Society

4 experts are featured in this series.

EP. 2 PTSD Risk Factors and Changes in the Brain

4 experts are featured in this series.

EP. 3 PTSD Symptoms

4 experts are featured in this series.

EP. 4 PTSD Diagnosis and Challenges

4 experts are featured in this series.

EP. 5 Tools for PTSD Diagnosis

4 experts are featured in this series.

EP. 6 PTSD Diagnosis in Clinical Settings

4 experts are featured in this series.

EP. 7 Treatment Options for PTSD

4 experts are featured in this series.

EP. 8 Use of PTSD Treatments in Clinical Practice

4 experts are featured in this series.

EP. 9 Emerging Treatments in PTSD

4 experts are featured in this series.

EP. 10 Concluding Thoughts on PTSD Management

4 experts are featured in this series.

EP. 11 Patient Case: Trauma and Impact of PTSD on Quality of Life

PTSD

EP. 12 Panel Shares Top 7 Insights Into Addressing PTSD

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Psychiatric Pharmacogenomics: An Overview

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

Evaluating Transdermal Asenapine in Schizophrenia